Objective:
To present findings from the VOYAGER study on the effectiveness of faricimab in reducing intraretinal and subretinal fluid in diabetic macular edema (DME).
Key Findings:
- Faricimab led to a significant reduction in intraretinal fluid, halving it by month 1.
- Subretinal fluid decreased to almost zero by month 6 in the analyzed subgroup.
- Results align with findings from randomized controlled trials.
Interpretation:
The early and meaningful reductions in retinal fluid suggest that faricimab is effective in real-world settings for treating DME.
Limitations:
- The analysis was conducted on a subset of participants with complete data for ROSA.
- As a noninterventional study, results may not fully represent all patient populations.
Conclusion:
The VOYAGER study provides encouraging real-world evidence supporting the use of faricimab for DME, with more data expected in the future.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.